Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Shuttle Pharmaceuticals Holdings Inc SHPH

Healthcare Biotechnology
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include... see more

Recent & Breaking News (NDAQ:SHPH)

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

GlobeNewswire 11 days ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire October 29, 2024

Shuttle Pharma Pays Off Senior Secured Convertible Note

GlobeNewswire October 29, 2024

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire October 29, 2024

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire October 28, 2024

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024

GlobeNewswire October 28, 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire September 16, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Accesswire September 11, 2024

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

GlobeNewswire September 5, 2024

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

GlobeNewswire September 4, 2024

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire August 28, 2024

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

GlobeNewswire August 26, 2024

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

GlobeNewswire August 14, 2024

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

GlobeNewswire July 19, 2024

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

GlobeNewswire June 18, 2024

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

GlobeNewswire May 22, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

GlobeNewswire May 14, 2024

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

GlobeNewswire April 23, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

GlobeNewswire April 3, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

PR Newswire March 22, 2024